 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > A faecal microbiota signature with high specificity for pancreatic cancer |
(Heidelberg University) (European Molecular Biology Laboratory) (Centro de Investigación Biomédica en Red de Oncología (CIBERONC)) (Centro Nacional de Investigaciones Oncológicas) (Heidelberg University) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (Philipps University Marburg Faculty of Medicine) (European Molecular Biology Laboratory) (University of Alcala de Henares) (Centro de Investigación Biomédica en Red de Oncología (CIBERONC)) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (University of Greifswald) (University of Greifswald) (Hospital Universitari Vall d'Hebron) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (Centro Nacional de Investigaciones Oncológicas) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (European Molecular Biology Laboratory) (European Foundation for the Study of Chronic Liver Failure) (Universitat Pompeu Fabra) (Centro de Investigación Biomédica en Red de Oncología (CIBERONC)) (Max Delbrück Center) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau)| Data: | 2022 |
| Resum: | Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. To explore the faecal and salivary microbiota as potential diagnostic biomarkers. We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case-control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case-control study (n=76), in the validation phase. Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0. 84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0. 94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19-9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible. |
| Ajuts: | Ministerio de Economía y Competitividad RD12/0036/0073 Instituto de Salud Carlos III PI17/02303 Ministerio de Economía y Competitividad PI15/01573 Instituto de Salud Carlos III PI18/01347 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Cancer prevention ; Intestinal microbiology ; Pancreatic cancer ; Pancreatic tumours ; Screening |
| Publicat a: | Gut, Vol. 71 (march 2022) , p. 1359-1372, ISSN 1468-3288 |
